Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jul;20(4):817-30.
doi: 10.1111/j.1750-3639.2010.00390.x.

General aspects and neuropathology of X-linked adrenoleukodystrophy

Affiliations
Review

General aspects and neuropathology of X-linked adrenoleukodystrophy

Isidro Ferrer et al. Brain Pathol. 2010 Jul.

Abstract

X-adrenoleukodystrophy (X-ALD) is a metabolic, peroxisomal disease affecting the nervous system, adrenal cortex and testis resulting from inactivating mutations in ABCD1 gene which encodes a peroxisomal membrane half-adenosine triphosphate (ATP)-binding cassette transporter, ABCD1 (or ALDP), whose defect is associated with impaired peroxisomal beta-oxidation and accumulation of saturated very long-chain fatty acids (VLCFA) in tissues and body fluids. Several phenotypes are recognized in male patients including cerebral ALD in childhood, adolescence or adulthood, adrenomyeloneuropathy (AMN), Addison's disease and, eventually, gonadal insufficiency. Female carriers might present with mild to severe myeloneuropathy that resembles AMN. There is a lack of phenotype-genotype correlations, as the same ABCD1 gene mutation may be associated with different phenotypes in the same family, suggesting that genetic, epigenetic, environmental and stochastic factors are probably contributory to the development and course of the disease. Degenerative changes, like those seen in pure AMN without cerebral demyelination, are characterized by loss of axons and secondary myelin in the long tracts of the spinal cord, possibly related to the impaired lipid metabolism of VLCFAs and the associated alterations (ie, oxidative damage). Similar lesions are encountered following inactivation of ABCD1 in mice (ABCD1(-)). A different and more aggressive phenotype is secondary to cerebral demyelination, very often accompanied by inflammatory changes in the white matter of the brain and associated with activation of T lymphocytes, CD1 presentation and increased levels of cytokines, gamma-interferon, interleukin (IL)-1alpha, IL-2 and IL-6, Granulocyte macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor-alpha, chemokines and chemokine receptors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
X‐ALD, childhood cerebral form (cALD). A. Loss of myelin and axons in the white matter of the temporal lobe. B. Inflammatory infiltrates in the white matter at the edge of the demyelinating lesion. C. Infiltrating reactive CD68+ cells in the intermediate zone between the edge of demyelination and the demyelinated area. D. Hypertrophic astrocytes in the demyelinated area. Paraffin sections: A, B, D. hematoxylin and eosin; C. CD68 immunohistochemistry. B, bar = 200 µm; C, D, bar = 50 µm.
Figure 2
Figure 2
Pure adult cerebral X‐ALD. Gross neuropathological examination of the cerebral hemispheres at the levels of the striatum and globus pallidus (A), mid‐thalamus (B) and posterior part of the parietal lobes (C) show demyelination of the cerebral white matter largely sparing the subcortical fibers. Note the thinning of the anterior part of the corpus callosum and internal capsule. Demyelination is better seen by using myelin stains (Spielmeyer‐Vogt) (D).
Figure 3
Figure 3
Pure adult cerebral X‐ALD. A, B. Perivascular infiltrates of round cells and macrophages filled with granular material that is stained with hematoxylin and eosin (A) and luxol fast blue (B). Bar = 50 µm.
Figure 4
Figure 4
The dorsal column of the spinal cord in wild type: WT (A, E); ABCD1, ALD (B, F); ABCD2, ALDR (C, G); and double mutant ABCD1 /ABCD2 , 2KO (D, H) aged 20 months immunostained with anti‐synaptophysin (A–D) and anti‐ubiquitin (E–H) antibodies. Axonal swellings (arrows) are seen in ALD, ALDR and 2KO mice. Paraffin sections slightly counterstained with haematoxylin. Bar = 20 µm.

References

    1. Asheuer M, Bieche I, Laurendeau I, Moser A, Hainque B, Vidaud M, Aubourg P (2005) Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X‐linked adrenoleukodystrophy. Hum Mol Genet 14:1293–1303. - PubMed
    1. Aubourg P (1996) X‐linked adrenoleukodystrophy. In: Handbook of Clinical Neurology, Vinken PJ, Bruyn GW, Moser HW (eds), pp. 447–483. Elsevier: Amsterdam.
    1. Aubourg P, Adamsbaum C, Lavallard‐Rousseau MC, Lemaitre A, Boureau F, Mayer M, Kalifa G (1992) Brain MRI and electrophysiologic abnormalities in preclinical and clinical adrenomyeloneuropathy. Neurology 42:85–91. - PubMed
    1. Aubourg P, Adamsbaum C, Lavallard‐Rousseau MC, Rocchiccioli F, Cartier N, Jambaque I et al (1993) A two‐year trial of oleic and erucic acids (“Lorenzo's oil”) as treatment for adrenomyeloneuropathy. N Engl J Med 329:745–752. - PubMed
    1. Aubourg P, Blanche S, Jambaque I, Rocchiccioli F, Kalifa G, Naud‐Saudreau C et al (1990) Reversal of early neurologic and neuroradiologic manifestations of X‐linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 322:1860–1806. - PubMed

Publication types